SNY - Sanofi
After hours:
Chart Events
Commodity Channel Index
Performance Outlook
- Short Term2W - 6W
- Mid Term6W - 9M
- Long Term9M+
| Previous Close | 52.59 |
| Open | 52.89 |
| Bid | 52.51 x 800 |
| Ask | 54.61 x 1000 |
| Day's Range | 52.48 - 53.16 |
| 52 Week Range | 36.91 - 57.82 |
| Volume | |
| Avg. Volume | 1,736,445 |
| Market Cap | 132.319B |
| Beta (5Y Monthly) | 0.40 |
| PE Ratio (TTM) | 14.67 |
| EPS (TTM) | 3.58 |
| Earnings Date | N/A |
| Forward Dividend & Yield | 1.90 (3.62%) |
| Ex-Dividend Date | May 30, 2023 |
| 1y Target Est | 63.75 |
Fair Value
Related Research
ZacksRegeneron (REGN) Posts Upbeat Data From Multiple Myeloma Study
A mid-stage study data shows that treatment with Regeneron's (REGN) experimental antibody achieved a 71% objective response rate in heavily pre-treated multiple myeloma patients.
GlobeNewswirePress Release: Annual General Meeting of May 25, 2023 – Frédéric Oudéa new Chairman of the Board of Directors
Annual General Meeting of May 25, 2023 – Frédéric Oudéa new Chairman of the Board of Directors Approval of the financial statements for the fiscal year 2022Distribution of a cash dividend of €3.56 per share, with payment as of June 1st, 2023Board composition: Frédéric Oudéa becomes Independent Director and Chairman of the Board Paris, May 25, 2023. The Combined General Shareholders’ Meeting of Sanofi was held on May 25, 2023, under the chairmanship of Serge Weinberg. The General Meeting approved
BenzingaSanofi-Regeneron Highlight Dupixent Data, Say Drug Benefit Was Swift, Sustained
Regeneron Pharmaceuticals Inc (NASDAQ: REGN) and Sanofi SA (NASDAQ: SNY) presented results from a Phase 3 study of Dupixent (dupilumab) in adults currently on maximal standard-of-care inhaled therapy (triple therapy) with uncontrolled chronic obstructive pulmonary disease (COPD) and evidence of type 2 inflammation. Dupixent demonstrated a significant reduction in moderate or severe acute exacerbations by 30% compared to placebo, meeting the primary endpoint. Dupixent significantly improved lung
Motley Fool2 Bear Market Defying Stocks to Buy in May
This group of companies includes Sanofi (NASDAQ: SNY) and Axsome Therapeutics (NASDAQ: AXSM). France-based Sanofi is a biotech giant with a diversified portfolio of medicines and vaccines, although it is perhaps best known for being one of the leaders in the insulin market. The company grabbed headlines in this space earlier this year when it decided to cut the price of its top-prescribed insulin product, Lantus, by 78% and limit out-of-pocket costs to $35.
- GlobeNewswire
Press Release: Dupixent® (dupilumab) late-breaking Phase 3 COPD results presented at ATS and simultaneously published in the New England Journal of Medicine
Dupixent® (dupilumab) late-breaking Phase 3 COPD results presented at ATS and simultaneously published in the New England Journal of Medicine Dupixent is the first and only investigational biologic for COPD that has demonstrated a significant reduction in moderate or severe acute exacerbations by 30% compared to placeboDupixent is the first and only investigational biologic for COPD that has significantly improved lung function at 12 and 52 weeks, with numerical improvements seen as early as 2 w
Investopedia5 Things to Know Before Markets Open
President Biden said he was confident that negotiators would reach a deal on the debt ceiling and Fed Chair Jerome Powell is set to speak on monetary policy. Here’s what investors need to know today.
The Wall Street JournalSanofi Wins Supreme Court Patent Dispute With Amgen
The court said Amgen patents relating to its cholesterol drug Repatha shouldn’t have been granted by the patent office, handing a victory to rival pharmaceutical firm Sanofi.
PR NewswireSanofi Applauds Supreme Court Ruling Supporting Scientific Innovation by Striking Down Amgen's Asserted PCSK9 Patent Claims in Amgen v Sanofi
Sanofi (NASDAQ: SNY) is pleased with the United States Supreme Court's ruling in Amgen v. Sanofi et. al. The decision unanimously affirms the United States Federal Circuit Court's opinion that is favorable to Sanofi and Regeneron.
- Reuters
UPDATE 3-U.S. Supreme Court rules against Amgen bid to revive cholesterol drug patents
The U.S. Supreme Court on Thursday ruled against Amgen Inc in its bid to revive patents on its cholesterol-lowering drug Repatha in a legal clash with French rival Sanofi SA. The 9-0 ruling upheld a lower court's decision that had invalidated Amgen's patents on the grounds that the Thousand Oaks, California-based drugmaker had failed to provide a roadmap for recreating, or "enabling," the full scope of its claimed innovation. Conservative Justice Neil Gorsuch wrote for the court that "we agree with the lower courts that Amgen has failed to enable all that it has claimed, even allowing for a reasonable degree of experimentation."
- GlobeNewswire
Sanofi: Information concerning the total number of voting rights and shares – April 2023
Information concerning the total number of voting rights and shares, provided pursuant to article L. 233-8 II of the Code de commerce (the French Commercial Code) and article 223-16 of the Règlement général de l’Autorité des Marchés Financiers (Regulation of the French stock market authority) Sanofia French société anonyme with a registered share capital of 2,521,494,572 €Registered office : 46, avenue de la Grande Armée - 75017 Paris - FranceRegistered at the Paris Commercial and Companies Regi
FortuneSanofi CEO: ‘Europe’s lead in life sciences R&D is eroding–but co-localized hubs could allow it to keep up’
'Innovation is powered by more than just money,' writes Sanofi CEO Paul Hudson.
TheStreet.comThese 3 Global Drug Stocks Have a Prescription for High Yields
Let's review three pharma companies based outside the U.S. that promise reasonable valuations and solid dividend yields.
Investor's Business DailySanofi Says Its RSV Shot Significantly Cut Hospitalization Risk In Newborns
Sanofi said Friday its shot significantly reduced the risk of babies becoming hospitalized with RSV. But Sanofi stock dipped Friday.
BenzingaSanofi, AstraZeneca Release Real-World Data For Respiratory Syncytial Virus Antibody
The race to tap the respiratory syncytial virus (RSV) this season intensifies as Sanofi SA (NASDAQ: SNY) and AstraZeneca Plc (NASDAQ: AZN) have revealed data from a real-world trial of their candidate nirsevimab, a long-acting antibody. In November, nirsevimab was approved in Europe, dubbed Beyfortus, to prevent RSV-LRTD in newborns and infants during their first RSV season. The phase 3 HARMONIE study recruited over 8,000 infants 12 months and younger. Infants who received a single dose of the a
- GlobeNewswire
Press Release: Nirsevimab delivers 83% reduction in RSV infant hospitalizations in a real-world clinical trial setting
Nirsevimab delivers 83% reduction in RSV infant hospitalizations in a real-world clinical trial setting HARMONIE Phase 3b data reinforce nirsevimab’s consistent and high efficacy against infant hospitalizations due to RSVData presented at ESPID add to the body of evidence demonstrating nirsevimab’s protection against RSV-related lower respiratory tract disease (LRTD) and confirm its favorable safety profile in multi-country, real-world conditions Paris, May 12, 2023. New data from the HARMONIE P
- Reuters
UPDATE 1-Insulin makers testify on Capitol Hill over prices
PBMs negotiate with drugmakers for rebates and lower fees on behalf of employers and other clients, and reimburse pharmacies for prescriptions they dispense. Both sides blame each other for high drug prices. Testifying on Wednesday were the CEOs of major insulin manufacturers Eli Lilly and Co, Novo Nordisk, and Sanofi, which together control 90% of the U.S. market, and top PBM executives from CVS Health Corp, Cigna Group's Express Scripts, and UnitedHealth Group Inc's Optum RX, which control 80% of the prescription drug market.
- Reuters
CORRECTED-Pharma CEOs to testify in U.S. Senate hearing on insulin prices
The leaders of major insulin makers and pharmacy benefit managers (PBMs) are set to blame each other on Wednesday in their testimonies during a U.S. Senate committee hearing on making the life-saving drug more affordable. PBMs negotiate with drugmakers for rebates and lower fees on behalf of employers and other clients, and reimburse pharmacies for prescriptions they dispense. Both sides blame each other for high drug prices.
Insider Monkey15 Biggest Immunotherapy Companies in the World
In this article, we will take a look at the 15 biggest immunotherapy companies in the world. If you want to see more companies in this selection, go to the 5 Biggest Immunotherapy Companies in the World. The immunotherapy industry is a rapidly growing field that is focused on developing treatments that harness the power […]
Insider MonkeyKymera Therapeutics, Inc. (NASDAQ:KYMR) Q1 2023 Earnings Call Transcript
Kymera Therapeutics, Inc. (NASDAQ:KYMR) Q1 2023 Earnings Call Transcript May 6, 2023 Operator: Good morning, and welcome to the Kymera Therapeutics First Quarter 2023 Earnings Conference Call [Operator Instructions]. Please note that this event is being recorded today. I would now like to turn the conference over to the Chief Financial Officer, Bruce Jacobs. Please […]
ZacksDenali (DNLI) Q1 Earnings Miss Estimates, Pipeline in Focus
Denali (DNLI) delivers a wider Q1 loss while collaboration revenues surpass estimates.
- Thomson Reuters StreetEvents
Q1 2023 Regeneron Pharmaceuticals Inc Earnings Call
Q1 2023 Regeneron Pharmaceuticals Inc Earnings Call
InvestorPlace7 Blue-Chip Stocks to Buy in May 2023
While large-capitalization enterprises don’t offer much excitement, current circumstances may call for the best blue-chip stocks to buy. Frankly, it’s getting a little bit toasty on Wall Street, which is why stability may come at a premium. Naturally, the failure of First Republic – the third such collapse of a banking enterprise this year – generated plenty of jitters. Despite JPMorgan Chase (NYSE:JPM) CEO Jamie Dimon’s encouraging words that the FRC takeover averted a crisis, circumstances sti
BenzingaWhy Regeneron Pharmaceuticals Shares Are Trading Lower Today
Regeneron Pharmaceuticals Inc (NASDAQ: REGN) earned adjusted EPS of $10.09, down 12% Y/Y, beating the $9.60 Street estimate. Revenues decreased 6% Y/Y to $3.16 billion, down from $3.41 billion in Q4 FY22, beating the consensus of $3.00 billion. Revenues from REGEN-COV, covid-19 antibody cocktail, reached $613.2 million, down 4% Y/Y. In the first quarter of 2023, Dupixent global net sales (recorded by Sanofi) increased 37% to $2.49 billion versus the first quarter of 2022. Eylea U.S. net sales de
ZacksRegeneron (REGN) Q1 Earnings & Sales Top, Eylea Sales Decline
Regeneron (REGN) beats earnings and sales estimates in first-quarter 2023 fueled by Dupixent. However, sales of the lead drug Eylea declined yet again.
InvestorPlace7 Stock Upgrades and Downgrades Alerts You Cannot Ignore
Analyst stock upgrades and downgrades create powerful headlines that will move the underlying shares. Investors should take advantage of the price swings analysts create, especially when they make the wrong calls. Stock price changes are noisy. Investors may use the stock volatility to buy a stock at a temporary discount or sell on a spike. Among the seven companies discussed below, those with a strong revenue pipeline and earnings visibility are buys. In addition, they are typically large capit